Thompson J A, Filloux F M, Van Orman C B, Swoboda K, Peterson P, Firth S D, Bale J F
Division of Pediatric Neurology, Department of Pediatrics, The University of Utah, Primary Children's Medical Center, Salt Lake City, UT, USA.
Neurology. 2005 Jun 28;64(12):2029-32. doi: 10.1212/01.WNL.0000166950.35189.5E. Epub 2005 May 25.
Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.
在美国流行地区，婴儿肉毒中毒会导致婴儿出现急性延髓功能障碍、肌无力和呼吸衰竭。在2003年10月美国食品药品监督管理局批准肉毒中毒免疫球蛋白（BIG）之前，自20世纪70年代以来，婴儿肉毒中毒的治疗方法几乎没有变化。目前，建议静脉注射BIG以缩短病程并减少该疾病的潜在并发症。本文综述了二十年来婴儿肉毒中毒的治疗经验，并对BIG的作用和益处提供了当代观点。
